A Randomised Open-label Phase II Trial of Consolidation with Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy.
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Small cell lung cancer
- Focus Therapeutic Use
- Acronyms STIMULI
- 10 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 10 Jul 2019 Planned End Date changed from 1 Jan 2022 to 30 Nov 2020.
- 10 Jul 2019 Actual date last participant enrolled is 4/29/2019 and the anticipated date of last data collection is 30/11/2020.